Norges Bank
OPRX icon

Norges Bank’s OptimizeRx OPRX Stock Holding History

Norges Bank’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-53,600
Closed -$766K – 2019
2023
Q2 		$766K Sell
53,600
-300
-0.6% -$4.27K ﹤0.01% 1947
2023
Q1 		$789K Hold
53,900
– – ﹤0.01% 2023
2022
Q4 		$906K Buy
+53,900
New +$932K ﹤0.01% 2062

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Norges Bank's OPRX Position: Q3 2023 in Review

Norges Bank sold out of OptimizeRx (OPRX) in Q3 2023, closing a stake of 53,600 shares — an estimated $766K sold.

Norges Bank first reported a position in OPRX in Q4 2022 and held it in 3 quarters. The position peaked at $906K in Q4 2022. 94 funds tracked by Wall St. Rank hold OPRX as of Q3 2023.

  • Norges Bank reported no remaining OptimizeRx position as of Q3 2023 after selling out during the quarter.
  • Norges Bank sold 53,600 OptimizeRx shares in Q3 2023, an estimated $766K.
  • Norges Bank first reported a position in OptimizeRx in Q4 2022 and held it in 3 quarters.
  • Norges Bank's OptimizeRx position peaked at $906K in Q4 2022.
  • 94 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2023.

Based on Norges Bank's 13F filing for Q3 2023, filed 13 Nov 2023.